Why was LAB591 created?
There is currently a lack of funding to help translate basic research in disease-related biological pathways into focused drug discovery program. LAB591 seeks to address this unmet need, to stimulate the formation of new companies to develop ground-breaking therapies, and ultimately to generate patient benefit.
"Through this very fast and efficient process, we can address important issues in healthcare and bridge the funding gap from research to commercialization.”
Hilary Hehman, MS, JD
Director of Partnerships and Alliances, Fred Hutch
Our mission is three-pronged: To develop and identify commercializable assets based on disease-related novel biological pathways; to significantly shorten the drug discovery timeline and; to generate viable start-up companies with high potential for success.
The steering committee is composed of representatives from Fred Hutch, Evotec and Arix Bioscience.
Initial applications may be for Small Scale Awards (up to $50K to achieve basic proof of concept) or for Large Scale Awards (up to $250K and in exceptional cases, higher amounts).
LAB591 welcomes ad hoc applications, as well as applications in response to specific requests for proposals.
Applicants will benefit from financial support, technical expertise, and physical resources of LAB591 partners.
Meet Our Team
LAB591 is under the day-to-day administration of Fred Hutch, Evotec and Arix Bioscience. All successful projects are selected by the joint steering committee before being admitted into the program.
From 2015 to 2017, she worked for F. Hoffmann La Roche as International Business Leader Avastin Breast, Cervical and Ovarian Cancer, and since September 2017 she is back in Boston as Executive Vice President, Head BRIDGEs Partnerships North America for Evotec, building alliances with academics, biotechnology, pharma and financing partners.
Iva earned a Doctor of Philosophy from Bulgarian Academy of Sciences in Molecular Genetics and Masters of Business Administration from F.W. Olin Graduate School of Business at Babson College.